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ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA).
This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically
confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy. Patients were randomised
to receive p6 cycles of carboplatin area under the plasma concentration–time curve 6mgml
 1min and paclitaxel 175mgm
 2 (CP,
n¼36) or standard therapy plus ASA404 1200mgm
 2 (ASA404-CP, n¼37). There was little change in the systemic exposure of
either total or free carboplatin or paclitaxel on addition of ASA404. Safety profiles were similar and manageable in both groups, with
most adverse effects attributed to standard therapy. Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs
4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404
combination group compared with the standard therapy group. In conclusion, this study establishes the feasibility of combining
ASA404 with carboplatin and paclitaxel in patients with previously untreated, advanced NSCLC, demonstrating a manageable safety
profile and lack of adverse pharmacokinetic interactions. The results indicate that there may be a benefit associated with ASA404, but
this needs to be evaluated in a larger trial.
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The mainstay of treatment for advanced non-small cell lung cancer
(NSCLC) is platinum-based chemotherapy (Non-Small Cell Lung
Cancer Collaborative Group, 1995), often combined with paclitaxel
(Langer et al, 1995). However, an efficacy plateau has been reached
with chemotherapy; no regimen is clearly superior (Schiller et al,
2002), and adding a third cytotoxic agent increases toxicity without
improving outcome (Wakelee and Belani, 2005).
A new treatment strategy under investigation involves targeting
tumour vasculature with small-molecule vascular disrupting
agents (VDAs), such as the tubulin-depolymerising combretastatin
A-4-phosphate (C4AP) (Dowlati et al, 2002; Stevenson et al, 2003;
Rustin et al, 2003b) and the microtubule-independent ASA404
(5,6-dimethylxanthenone-4-acetic acid (DMXAA)), or anti-angio-
genic agents, such as the antibody bevacizumab. In a phase III
study, the combination of carboplatin, paclitaxel and bevacizumab
improved survival significantly compared with carboplatin and
paclitaxel alone in patients with advanced NSCLC of non-
squamous histology (Sandler et al, 2006).
The tumour-VDA, ASA404, induces apoptosis of tumour
vascular endothelial cells and cytokine production, leading to
tumour vascular collapse (Ching et al, 2002; Baguley, 2003;
Tozer et al, 2005). In animal models, this culminates in extensive
tumour necrosis predominantly within the tumour core (Zwi et al,
1994; Laws et al, 1995; Ching et al, 1999, 2004; Joseph et al, 1999).
The therapeutic potential of ASA404 appears to lie in its
combination with other treatments (Wilson et al, 1998; Murata
et al, 2001). In animal models, ASA404 acted synergistically with
chemotherapy (Pruijn et al, 1997; Siim et al, 2003; McKeage and
Kelland, 2006); therapeutic gains were most striking with taxanes.
Scheduling studies indicated that activity was optimised when
ASA404 was administered shortly after chemotherapy (Siim et al,
2003).
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sIn two phase I trials, 109 patients received ASA404 monotherapy
at doses of 6–4900mgm
 2 weekly or every 3 weeks (Jameson et al,
2003; Rustin et al, 2003a). ASA404 did not cause myelosuppression
and was generally well tolerated. Transient prolongation of heart
rate-corrected cardiac QT interval (QTc) was seen at high doses
(X2000mgm
 2). Transient, dose-dependent visual disturbances
were also noted. Dose-limiting toxicities were rapidly reversible
and included confusion, tremor, slurred speech, visual distur-
bance, anxiety, urinary incontinence and possible left ventricular
failure. The maximum tolerated dose (MTD) was 3700mgm
 2.
ASA404 produced two unconfirmed partial responses at 1100 and
1300mgm
 2, and 28 patients had a best response of stable disease.
Dynamic contrast-enhanced magnetic resonance imaging showed
reductions in tumour blood flow at sub-MTD doses (Galbraith
et al, 2002). A third phase I study investigated the potential for
cardiac and ophthalmic toxicity and found ASA404 doses of 1200
and 1800mgm
 2 to be well tolerated, with no significant effect on
QTc interval or deterioration in ophthalmic variables (McKeage
et al, 2006). Near-maximal levels of the tumour vascular damage
biomarker 5-hydroxyindoleacetic acid (5-HIAA) were seen at these
doses (Baguley et al, 1997), and ASA404 plasma concentrations
were within the preclinical therapeutic range (McKeage et al,
1991).
We conducted this randomised phase II study to determine the
feasibility of combining ASA404 1200mgm
 2 with carboplatin and
paclitaxel, to examine the potential for pharmacokinetic interac-
tions between components of this regimen and to evaluate its
safety and efficacy in patients with previously untreated advanced
NSCLC.
MATERIALS AND METHODS
Men and women X18 years with histologically confirmed,
locally advanced or metastatic NSCLC (stage IIIb/IV, incurable
by surgery/radiotherapy), with X1 unidimensionally measurable
lesion according to the Response Evaluation Criteria in Solid
Tumors (RECIST) (Therasse et al, 2000) and no previous chemo-
therapy were eligible. Other requirements included Karnofsky
performance status X70%, life expectancy X3 months and
adequate haematological, renal and hepatic function.
Main exclusion criteria were major surgery/radiotherapy (unless
palliative) p4 weeks before enrolment, central nervous system
metastases, small cell or mixed lung cancer, clinically significant
cardiac arrhythmia or known QTc interval prolongation, severe or
uncontrolled systemic disease, pregnancy, use of medication
known to affect systemic serotonin levels or QTc interval p2
weeks before ASA404 administration or an expected need for such
treatment during the study.
Patients were recruited from 15 centres in New Zealand,
Australia, Germany and France. The study was conducted
according to the Declaration of Helsinki. Ethics committee
approval and informed patient consent were obtained.
Study design
This randomised, open-label, phase II study tested the addition of
ASA404 1200mgm
 2 to a standard therapy regimen comprising
carboplatin dosed to area under the plasma concentration–time
curve (AUC) 6mgml
 1min plus paclitaxel at an FDA-approved
dose of 175mgm
 2.
Patients were allocated to receive ASA404 1200mgm
 2 plus
carboplatin and paclitaxel (ASA404-CP) or carboplatin and
paclitaxel alone (CP). Randomisation was conducted centrally,
with stratification for disease stage, performance status and histo-
logical type. On day 1 of each cycle, patients received paclitaxel
as a 3-h IV infusion, then carboplatin as a 30-min IV infusion,
then, if allocated, ASA404 as a 20-min IV infusion.
As this was the first experience of ASA404 in combination with
carboplatin and paclitaxel in humans, a single patient received
the combination with ASA404 at a lower dose of 600mgm
 2
(six cycles) to check safety before randomisation began. Then, the
first six patients randomised to the ASA404 group were recruited
according to early stopping rules to monitor safety before the
study progressed further. A detailed pharmacokinetic (PK)
evaluation of the ASA404-CP combination was undertaken in
these first six patients to assess the potential for drug interaction
between ASA404 and paclitaxel and carboplatin in combination.
To facilitate this, the ASA404 regimen was modified, with the first
cycle of treatment comprising CP, then up to five cycles of
ASA404-CP, and finally, for patients still on study, a single cycle of
ASA404 alone.
On the basis that no more than one dose-limiting toxicity (DLT),
not clearly attributed to paclitaxel or carboplatin, was observed in
the first six patients, enrolment continued until approximately 35
eligible patients were recruited in each of the ASA404-CP and CP
groups. Treatment was given every 21 days for six cycles or until
withdrawal, whichever was earlier. Within-patient dose modifica-
tion of ASA404 or carboplatin, and crossover between the ASA404-
CP and CP arms were not permitted. The dose of paclitaxel
remained unaltered unless dose reduction was required due to
toxicity attributed to these agents.
Assessments
Tumours were measured using computed tomography or magnetic
resonance imaging scans. Tumour response was evaluated using
RECIST and categorised as complete (CR), partial (PR), stable
disease (SD) or progressive disease (PD). Response was confirmed
by examination X4 weeks after first assessment. An independent
outcomes committee carried out a blinded radiological review of
all tumour assessments.
Safety assessments included a symptom-directed clinical exam-
ination before each cycle, 8 and 15 days after drug administration
(first six patients only) and at the safety follow-up visit. Laboratory
safety assessments of haematology and biochemistry parameters
were conducted at these same time points.
Intensive electrocardiographic assessments were conducted
throughout the study. Three standard 12-lead ECGs were acquired
during the 30min before paclitaxel administration (at cycles 1, 2
and 6 for the first six patients receiving ASA404; at cycles 1 and 6
for all other patients), and at the end of carboplatin infusion
(at cycle 1 for the first six patients receiving ASA404). Single ECGs
were collected immediately before administration of ASA404 then
at 10, 20, 60min and 1, 2 and 4h from the start of the ASA404
infusion (at cycles 2 and 6 for the first six patients receiving
ASA404; at cycles 1 and 6 for all other patients). Electrocardio-
grams were also collected immediately before paclitaxel infusion
and ASA404 infusion, and 1h from the start of infusion (at cycles
3, 4 and 5 for the first six patients receiving ASA404; at cycles 2–5
for all other patients).
If a patient developed a QTc interval (Bazett’s correction)
4520ms (men) or 4540ms (women), further ECGs were acquired
until the QTc interval returned to within 30ms of baseline on two
consecutive ECGs.
In patients receiving ASA404, ophthalmic tests were performed
before treatment and at follow-up. These included best-corrected
visual acuity, ophthalmological examination, contrast sensitivity,
colour vision/colour contrast sensitivity and central visual field.
For the first six patients recruited according to early stopping
rules, serial PK samples were collected and analysed after
carboplatin and paclitaxel dosing at cycle 1, after ASA404, carbo-
platin and paclitaxel dosing at cycle 2, and after ASA404 mono-
therapy, 3 weeks after the end of cycle 6. Total and free
concentrations for each drug were determined before infusion, at
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sthe end of infusion and at various intervals following the end of
infusion.
In addition, plasma samples were analysed for 5-HIAA
concentration at 2 and 4h following the start of ASA404 dosing
on day 1 of cycle 2.
All patients attended a screening visit p28 days before
treatment, a study visit every week and a follow-up visit 4 weeks
after study completion/withdrawal. Tumours were measured every
6 weeks until disease progression. Survival was assessed every 3
months.
Statistical methodology and analysis
Study populations were defined prospectively. Eligible patients met
the inclusion criteria and received X1 dose of study treatment. An
intention-to-treat (ITT) population (all patients allocated to
treatment) was not prospectively defined.
According to the protocol, efficacy analyses were performed on
all eligible patients who received ASA404-CP or CP and safety
analyses were performed on all patients who received X1 dose of
study treatment. The single patient who received ASA404 at a dose
of 600mgm
 2 was excluded from the analysis of safety and
efficacy.
Primary safety outcomes were treatment-emergent adverse
events (AEs), laboratory abnormalities, effect on QTc interval
and ophthalmic toxicity. A treatment-emergent AE was defined as
any unfavourable and unintended sign, symptom or disease
temporally associated with the use of a medicinal product
(including abnormal laboratory findings or worsening of pre-
existing conditions), whether or not considered related to the
study drug.
Adverse events were listed using MedDRA coding and graded
according to the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 3.0, or as mild,
moderate or severe if NCI-CTCAE were not applicable. Relation-
ships of AEs to treatment were assessed as definite, probable,
possible or unrelated.
Plasma concentrations of ASA404, carboplatin and paclitaxel
were summarised at each time point, for each ASA404 dose and
treatment cycle. Mean maximum observed concentration (Cmax)
and AUC from time of dosing to time of last observation (AUC(0–t))
were calculated and expressed as a ratio (co-administration/alone).
Principal efficacy end points were objective response rates, time
to tumour progression (TTP) and survival. According to the
protocol, TTP and survival were defined as time from treatment
initiation to first objective documentation of progression or death,
respectively. In the absence of progression (TTP end point) or
death (survival end point), data were ‘censored’ at the last follow-
up date. Kaplan–Meier curves were fitted for TTP and survival and
used to estimate median and 1-year values.
Treatment differences between the ASA404 plus CP and CP-
alone groups were assessed by calculating the percentage
difference (for response rates) and the hazard ratio (for time to
event end points) with the corresponding 95% confidence interval
and P-value. Statistically significant differences are indicated by
Po0.05.
A total sample size of 70 patients was fixed. Assuming an overall
response rate of 23% in the ASA404-CP arm, then the lower limit
of the 95% confidence interval would be at least 10%.
RESULTS
Patient demographics and disposition
Of the 76 patients allocated to treatment, three were excluded from
the safety population as they received no study medication
(ASA404-CP, n¼2; CP, n¼1); the safety population therefore
comprised 73 patients (ASA404-CP, n¼37; CP, n¼36). Three
treated patients from the ASA404-CP group were excluded from
the eligible population because they did not meet inclusion criteria
(n¼1) or withdrew before receiving ASA404 (n¼2); the eligible
population therefore comprised 70 patients (ASA404-CP, n¼34,
CP, n¼36).
The groups were well balanced for pretreatment characteristics
(Table 1). Approximately one-third of patients had squamous cell
carcinoma.
Treatment
The average number of chemotherapy cycles was higher in the
ASA404-CP group than in the CP group (4.3 and 3.8 cycles per
patient, respectively). Eleven patients in the ASA404-CP group and
seven in the CP group required paclitaxel dose reduction. Cycles
were delayed more frequently in the ASA404-CP group than in the
CP group (17.6 and 7.4% of all cycles, respectively).
Pharmacokinetics
Pharmacokinetic evaluation was performed for the first six
patients with the objective of assessing the potential for drug
interaction between ASA404 and paclitaxel and carboplatin.
On cycle 1 for these six patients, the CP combination was given
alone and PK parameters were found to be consistent with
published values (Patnaik et al, 2006). On cycle 2, CP was co-
administered with ASA404 and the PK parameters were compared
with CP alone. Mean PK parameters for carboplatin and paclitaxel
on cycle 2, expressed as ratio of those on cycle 1, are shown in
Table 2. Co-administration of ASA404 did not fundamentally alter
the PK parameters of either carboplatin or paclitaxel.
On cycle 7, ASA404 was administered alone and PK parameters
were consistent with those reported previously from phase I
studies (McKeage et al, 2006) and with those when co-
administered with CP in this study. Mean PK parameters for
ASA404 on cycle 2, expressed as a ratio of those on cycle 7, are
shown in Table 2. Co-administration did not alter the mean
systemic exposure to total ASA404; however, the Cmax and AUC
Table 1 Baseline characteristics of randomised patients (safety popula-
tion)
ASA404-CP
(n¼37) CP (n¼36)
Men, n (%) 23 (62.2) 24 (66.7)
Women, n (%) 14 (37.8) 12 (33.3)
Age (years), mean±s.d. 59.4±8.91 61.0±10.76
Histological subtype, n (%)
Squamous cell carcinoma/undifferentiated 11 (29.7) 11 (30.6)
Adenocarcinoma 25 (67.6) 22 (61.1)
Large cell carcinoma 0 2 (5.6)
Other 1 (2.7) 1 (2.8)
Stage, n (%)
IIIb 11 (29.7) 13 (36.1)
IV 26 (70.3) 23 (63.9)
Karnofsky performance status, n (%)
70 1 (2.7) 3 (8.3)
80 9 (24.3) 9 (25.0)
90 17 (45.9) 14 (38.9)
100 10 (27.0) 10 (27.8)
ASA404-CP¼ASA404 combined with carboplatin and paclitaxel; CP¼carboplatin
and paclitaxel; s.d.¼standard deviation.
ASA404 plus carboplatin and paclitaxel in advanced NSCLC
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svalues for free ASA404 were increased approximately six- and
eight-fold, respectively. Systemic exposure was markedly higher
for total ASA404 compared with free ASA404, as expected for an
agent that is extensively protein bound (Jameson et al, 2003).
Pharmacodynamics
Peak levels of 5-HIAA occurred 2h after ASA404 dosing. Mean
concentrations (n¼5) at this time point were 137.2±46.6nM,
representing an increase of 80.6±26.0nM from baseline. This
relative increase is similar to that seen with ASA404 1200mgm
 2
in phase I studies (Rustin et al, 2003a; McKeage et al, 2006).
Safety
Overall safety profiles were generally similar in the ASA404-CP and
CP groups (Table 3), and for squamous and non-squamous
patients. Most AEs and serious AEs (SAEs) were attributed to
standard therapy components. The proportions of patients with
AEs, ASA404- or CP-related AEs, SAEs and deaths, or study
discontinuations due to AEs, were similar in the two groups.
The most frequently occurring AEs attributed to ASA404 were
infusion site pain, nausea, vomiting and anaemia. The only SAE
directly attributed to ASA404 was asthenia in one patient.
The most common grade 3/4 toxicities are shown in Table 4.
Grade 3/4 neutropenia, thrombocytopenia, infection, hypokalemia
and infusion site burning or pain occurred more frequently in the
ASA404-CP group, whereas grade 3/4 hyperglycaemia, neuropathy
and anaemia occurred more frequently in the CP group.
Other differences noted between the two groups were four grade 3
respiratory AEs (dyspnea (n¼2), pneumothorax and productive
cough) occurring only in the ASA404-CP group and four grade 3
infections (chronic bronchitis, lung infection, urinary tract infection
and viral diarrhoea) occurring in the ASA404-CP group vs one grade
3 infection (lower respiratory tract) occurring in the CP group.
Grade 3/4 haematological abnormalities occurred in 78.4 and
63.9% patients in the ASA404-CP and CP groups, respectively. The
incidence of neutropenia at grade 3/4 was higher in the ASA404-CP
group (62.2%) than in the CP group (38.9%) (difference of 23.3%,
95% CI 1.0, 45.6). Maximal decreases in neutrophil counts occur-
red at day 15 after cycle 6 in both groups. Mean absolute
neutrophil count fell from 7.54±3.31 10
9l
 1 at baseline to
1.14±1.0 10
9l
 1 in the ASA404-CP group, and from 8.23±
4.76 10
9l
 1 to 1.54±0.75 10
9l
 1 in the CP group. Laboratory
data also showed that there was a higher overall incidence of
thrombocytopenia (all grades) in the ASA404-CP group (62.2 vs
44.4%). Other haematological toxicities were similar in the two
treatment arms.
The incidences of cardiac AEs and SAEs were higher in the
ASA404-CP group than in the CP group (18.9 and 10.8% vs 8.3 and
2.8%, respectively). Four patients in the ASA404-CP group had
cardiac SAEs. These were transient/reversible and included one
instance each of tachyarrhythmia (cycle 1, grade 4), cardiomyo-
pathy (cycle 3, patient withdrawn), myocardial ischaemia (cycles 3
and 5) and angina pectoris (cycle 3, grade 3). Three of these
patients had a history of cardiovascular disease. Electrocardiogram
analyses showed only one patient in the ASA404-CP group with a
prolonged QTc interval.
No patient showed significant deterioration in ophthalmic
variables after ASA404 treatment. Five AEs associated with visual
function (irritation, blurred vision or visual disturbance) were seen
in the ASA404-CP group and four were seen in the standard
therapy group (blurred vision or visual disturbance). All visual
function AEs were of ograde 3 severity.
Adverse events leading to withdrawal included disease progres-
sion (ASA404-CP, n¼1; CP, n¼3); anaphylactic reaction,
paclitaxel reaction, hypersensitivity or premedication reaction
(ASA404-CP, n¼1; CP, n¼3); leucopenia, neutropenia or
thrombocytopenia (ASA404-CP, n¼2; CP, n¼1); peripheral
neuropathy (CP, n¼1); cardiomyopathy (ASA404-CP, n¼1);
and multiple chemotherapy toxicities (CP, n¼1).
Seven deaths occurred on-study in the safety population
(ASA404-CP, n¼4; CP, n¼3). These were attributed to disease
progression (ASA404-CP, n¼2; CP, n¼1), pulmonary oedema
(CP, n¼1), pulmonary haemorrhage (CP, n¼1), sepsis (ASA404-
CP, n¼1) and non-obvious reasons (ASA404-CP, n¼1).
Efficacy
Table 5 shows RECIST response outcomes. Investigator assessment
gave a best overall response of PR, with 34.4% (95% CI 17.9, 50.8)
and 29.0% (95% CI 13.1, 45.0) responses confirmed in the ASA404-
CP group and CP group, respectively.
Independent assessment showed that a greater proportion of
patients receiving ASA404 had a best overall response of PR with
31.3% (95% CI 15.2, 47.3) vs 22.2% (95% CI 6.5, 37.9) with CP,
Table 2 Ratios (co-administration/alone
a) of mean PK parameters for CP cycle 2/cycle 1 and for ASA404 cycle 2/cycle 7 (n¼6)
Total carboplatin
b Free carboplatin
b Paclitaxel
c Paclitaxel metabolite
c Total ASA404
d Free ASA404
d
AUC(0 t) 1.19 1.38 1.10 0.96 1.05 7.95
95% CI 0.97, 1.41 0.98, 1.77 0.93, 1.27 0.62, 1.29 0.46, 1.64 2.05, 13.84
Cmax 1.26 1.36 0.88 1.04 1.01 5.72
95% CI 0.76, 1.76 0.37, 2.35 0.69, 1.07 0.69, 1.40 0.50, 1.52 2.01, 9.43
aIn cycle 1 CP was given alone, in cycle 2 CP was co-administered with ASA404 and in cycle 7 ASA404 was given alone.
bt¼20.25h for carboplatin.
ct¼45h for paclitaxel.
dt¼43.75h for ASA404.
Table 3 Summary of treatment-emergent adverse events (safety
population)
No. of patients (%)
ASA404-CP (n¼37) CP (n¼36)
X1 adverse event 34 (91.9) 36 (100.0)
Related to ASA404 27 (73.0) —
Related to standard therapy 28 (75.7) 31 (86.1)
Grade 1
a/mild
b 3 (8.1) 4 (11.1)
Grade 2
a/moderate
b 6 (16.2) 8 (22.2)
Grade 3
a/severe
b 17 (45.9) 22 (61.1)
Grade 4
a,b 5 (13.5) 0
Grade 5
a,b 3 (8.1) 2 (5.6)
X1 serious adverse event 16 (43.2) 17 (47.2)
Related to ASA404 1 (2.7) 0
Related to standard therapy 5 (13.5) 6 (16.7)
Adverse event leading to death 2 (5.4) 2 (5.6)
Adverse event leading to withdrawal 5 (13.5) 9 (25.0)
ASA404-CP¼ASA404 combined with carboplatin and paclitaxel; CP¼carboplatin
and paclitaxel.
aNational Cancer Institute Common Terminology Criteria for Adverse
Events grading.
bWorst severity grade.
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for response.
Median TTP by investigator assessment was 5.4 months in the
ASA404-CP group and 4.4 months in the CP group (Figure 1). The
risk of progression was reduced by 14% in the ASA404-CP group,
with a hazard ratio of 0.86, 95% CI 0.51, 1.45, and P¼0.56 (for the
ITT population: hazard ratio 0.94, 95% CI 0.56, 1.57, P¼0.82).
Median survival was 14.0 months in the ASA404-CP group and
8.8 months in the CP group (Figure 2). The risk of death was
reduced by 27% in the ASA404-CP group, with a hazard ratio of
0.73, 95% CI 0.39, 1.38, and P¼0.33 (for the ITT population:
hazard ratio 0.86, 95% CI 0.47, 1.57, P¼0.63). One-year survival
was 50.0% in the ASA404-CP group and 42.1% in the CP group.
DISCUSSION
This randomised phase II study evaluated the feasibility of adding
the Tumour-VDA ASA404 to a standard regimen of carboplatin
and paclitaxel in patients with previously untreated, advanced
NSCLC.
The study showed that when ASA404 was co-administered with
carboplatin and paclitaxel, there was little change in the systemic
exposure or disposition of either total or free carboplatin or
paclitaxel/6-alpha-hydroxy paclitaxel. Similarly, co-administration
with this standard therapy did not markedly alter the systemic
exposure of total ASA404. However, the concentration of free
ASA404 was increased, suggesting that the chemotherapy drugs or
excipients altered the partitioning of ASA404 within plasma.
Table 4 Most common grade 3 and 4 toxicities (safety population)
No. of patients (%)
ASA404-CP (n¼37) CP (n¼36)
Toxicity Grade 3 Grade 4 Grade 3 Grade 4
Neutropenia 8 (21.6) 15 (40.5) 10 (27.8) 4 (11.1)
Leukopenia 5 (13.5) 5 (13.5) 9 (25.0) 1 (2.8)
Alopecia 7 (18.9) 1 (2.7) 10 (27.8) 0
Hyperglycaemia 5 (13.5) 0 9 (25.0) 0
Neuropathy 2 (5.4) 0 7 (19.4) 0
Anaemia 3 (8.1) 0 5 (13.9) 0
Thrombocytopenia 2 (5.4) 2 (5.4) 2 (5.6) 0
Gastrointestinal disorders 3 (8.1) 0 2 (5.6) 1 (2.8)
Infection 4 (10.8) 0 1 (2.8) 0
Arthralgia, back or extremity pain 2 (5.4) 0 3 (8.3) 0
Cardiac disorders 3 (8.1) 1 (2.7) 1 (2.8) 0
Hypokalaemia 3 (8.1) 0 0 0
Respiratory, thoracic and mediastinal 3 (8.1) 0 0 0
Infusion site burning/pain 2 (5.4) 0 0 0
Dehydration 1 (2.7) 0 1 (2.8) 0
Anaphylactic shock or hypersensitivity 0 0 2 (5.6) 0
Neoplasms benign, malignant and unspecified 0 0 2 (5.6) 0
Flushing or hypotension 0 0 2 (5.6) 0
Febrile neutropenia 0 1 (2.7) 1 (2.8) 0
ASA404-CP¼ASA404 combined with carboplatin and paclitaxel; CP¼carboplatin and paclitaxel.
Table 5 Tumour response rate (eligible population)
No. of patients (%)
ASA404-CP
(n¼34)
CP
(n¼36)
Investigator assessment
Number of patients available for
assessment
32 (100.0) 31 (100.0)
Partial response (confirmed) 11 (34.4) 9 (29.0)
Partial response (unconfirmed) 2 (6.3) 3 (9.7)
Stable disease 14 (43.8) 10 (32.3)
Progressive disease 5 (15.6) 9 (29.0)
Independent assessment
Number of patients available for
assessment
a
32 (100.0) 27 (100.0)
Partial response 10 (31.3) 6 (22.2)
Stable disease 21 (65.6) 19 (70.4)
Progressive disease 1 (3.1) 2 (7.4)
ASA404-CP¼ASA404 combined with carboplatin and paclitaxel; CP¼carboplatin
and paclitaxel.
aTumour response could not be evaluated in 11 eligible patients by
independent assessment due to: patient death before second tumour assessment
(n¼3); patient withdrawal before second tumour assessment (n¼3); disease
progression after cycle 1 and no subsequent scans available (n¼2); no target lesion
present (n¼2); or no baseline scan available (n¼1).
Treatment
Median months (95% CI)
Hazard ratio (95% CI) = 0.86 (0.5, 1.4)
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Figure 1 Kaplan–Meier estimate of the time to tumour progression;
eligible population (ASA404-CP n¼34, CP n¼36).
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generally well tolerated and did not produce prohibitive additional
toxicity. The ASA404-CP group had a similar overall safety profile
to the CP group in that the incidences of AEs, SAEs and deaths or
study discontinuations due to AEs were similar. The higher
incidences of neutropenia, thrombocytopenia and infection in the
ASA404-CP group compared with the CP group were not expected
on the basis of the safety profile for ASA404 monotherapy
(Jameson et al, 2003; Rustin et al, 2003a; McKeage et al, 2006).
However, these were generally manageable and acceptable.
Intensive assessments showed that ophthalmic AEs occurred
with similar incidences in the ASA404-CP and CP groups. No
patient showed clinically relevant deterioration in ophthalmologi-
cal parameters after ASA404 treatment. This suggests that ASA404
1200mgm
 2 can be combined with carboplatin and paclitaxel
without the potential for the ophthalmic AEs seen at higher
monotherapy doses (Galbraith et al, 2002; McKeage et al, 2006).
The incidence of cardiac AEs and SAEs was higher in the
ASA404-CP group than in the CP group, although a causal
relationship to ASA404 was not established. It can be noted that
most of the cardiac SAEs in the ASA404-CP group occurred in
patients with known cardiovascular disease. Furthermore, in phase
I studies of ASA404, the predominant cardiac AE was QTc interval
prolongation (Jameson et al, 2003; McKeage et al, 2006), of which
there was a low incidence in this study. Nonetheless, as cardiac
toxicity could result from the mechanism of action of VDAs
(Cooney et al, 2004), the cardiac safety profile of ASA404 should
continue to be monitored in future studies.
Although the study was not powered to compare efficacy
outcomes statistically, the ASA404 combination appeared to
improve a range of efficacy end points compared with carboplatin
and paclitaxel alone – most notably overall survival. Response
rates and survival in the CP group were similar to those reported
previously for a carboplatin and paclitaxel regimen in patients with
advanced NSCLC (Schiller et al, 2002).
The magnitude of improvement in TTP was more modest than
that seen for overall survival. One possible explanation is that
radiological measurements and RECIST may not detect the
antitumour effects exerted by ASA404 because these are pre-
dominantly at the tumour core.
In a phase II study, addition of bevacizumab to a carboplatin
and paclitaxel regimen in the same setting as in our study was
associated with fatal pulmonary haemorrhage in patients with
squamous histology (Johnson et al, 2004). A more recent study of
the addition of the anti-angiogenic multiple kinase inhibitor
sorafenib to carboplatin and paclitaxel also indicated a higher
mortality rate in sorafenib-treated patients with squamous NSCLC
(Scagliotti et al, 2008). Despite approximately one-third of patients
in our study having squamous histology, only one episode of
major pulmonary haemorrhage was documented and this occurred
in the CP group. Other vascular-related side effects associated with
bevacizumab (hypertension, proteinuria and epistaxis) (Johnson
et al, 2004) were not prominent in the ASA404-CP group.
In conclusion, this study establishes the feasibility of combining
ASA404 with a standard chemotherapy regimen of carboplatin and
paclitaxel in patients with previously untreated, advanced NSCLC.
The manageable safety profile, lack of adverse pharmacokinetic
interactions and apparent improvements in various efficacy
parameters associated with the addition of ASA404 to carboplatin
and paclitaxel support the initiation of a phase III trial of sufficient
size to test this novel combination regimen with statistical power.
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